NEW YORK, April 17, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014

http://www.reportlinker.com/p0770879/Hormone-Refractory-Castration-Resistant-Androgen-Independent-Prostate-Cancer-Global-Clinical-Trials-Review-H1-2014.html

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, "Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" provides data on the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Introduction 8
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer 8
Report Guidance 8
Clinical Trials by Region 9
Clinical Trials and Average Enrollment by Country 10
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
Top Five Countries Contributing to Clinical Trials in Europe 13
Top Countries Contributing to Clinical Trials in North America 14
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 15
Top Five Countries Contributing to Clinical Trials in Central and South America 16
Clinical Trials by G7 Countries: Proportion of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer to Oncology Clinical Trials 17
Clinical Trials by Phase in G7 Countries 18
Clinical Trials in G7 Countries by Trial Status 19
Clinical Trials by E7 Countries: Proportion of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer to Oncology Clinical Trials 20
Clinical Trials by Phase in E7 Countries 21
Clinical Trials in E7 Countries by Trial Status 22
Clinical Trials by Phase 23
In Progress Trials by Phase 24
Clinical Trials by Trial Status 25
Clinical Trials by End Point Status 26
Unaccomplished Trials of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer 27
Subjects Recruited Over a Period of Time 35
Clinical Trials by Sponsor Type 36
Prominent Sponsors 37
Top Companies Participating in Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials 38
Prominent Drugs 40
Latest Clinical Trials News on Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer 41
Feb 11, 2014: OncoGenex Announces Target Number of Events Reached in Phase 3 SYNERGY Trial of Custirsen in Metastatic Castrate-Resistant Prostate Cancer 41
Nov 12, 2013: Medivation and Astellas Initiate Trial Evaluating Benefit of Continued Enzalutamide Treatment Beyond Disease Progression in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer 41
Sep 12, 2013: Bristol-Myers Squibb Reports Results for Phase 3 Trial of Yervoy in Previously-Treated Castration-Resistant Prostate Cancer 42
Jul 09, 2013: Bellicum Pharmaceuticals Initiates Clinical Trial with Novel Controlled Dendritic Cell Immunotherapy in Metastatic Castrate Resistant Prostate Cancer 43
May 23, 2013: University Of Michigan Researchers Conduct Phase II Clinical Trial To Test Targeting Prostate Cancer Treatment 44
Clinical Trial Profiles 45
Clinical Trial Overview of Top Companies 45
Sanofi 45
Clinical Trial Overview of Sanofi 45
Johnson & Johnson 49
Clinical Trial Overview of Johnson & Johnson 49
Novartis AG 53
Clinical Trial Overview of Novartis AG 53
Astellas Pharma Inc. 56
Clinical Trial Overview of Astellas Pharma Inc. 56
Takeda Pharmaceutical Company Limited 58
Clinical Trial Overview of Takeda Pharmaceutical Company Limited 58
Bristol-Myers Squibb Company 60
Clinical Trial Overview of Bristol-Myers Squibb Company 60
Bayer AG 62
Clinical Trial Overview of Bayer AG 62
Medivation, Inc. 64
Clinical Trial Overview of Medivation, Inc. 64
AstraZeneca PLC 66
Clinical Trial Overview of AstraZeneca PLC 66
Dendreon Corporation 68
Clinical Trial Overview of Dendreon Corporation 68
Clinical Trial Overview of Top Institutes / Government 69
National Cancer Institute 69
Clinical Trial Overview of National Cancer Institute 69
The University of Texas M. D. Anderson Cancer Center 75
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 75
University of California, San Francisco 77
Clinical Trial Overview of University of California, San Francisco 77
Memorial Sloan Kettering Cancer Center 78
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 78
Duke University 79
Clinical Trial Overview of Duke University 79
Barbara Ann Karmanos Cancer Institute 80
Clinical Trial Overview of Barbara Ann Karmanos Cancer Institute 80
Swiss Group for Clinical Cancer Research 81
Clinical Trial Overview of Swiss Group for Clinical Cancer Research 81
University of Wisconsin Madison 82
Clinical Trial Overview of University of Wisconsin Madison 82
Stanford University 83
Clinical Trial Overview of Stanford University 83
Five Key Clinical Profiles 84
Appendix 226
Abbreviations 226
Definitions 226
Research Methodology 227
Secondary Research 227
About GlobalData 228
Contact Us 228
Disclaimer 228
Source 229

List of Tables

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials by Region, 2014* 9
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 10
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 11
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 12
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 13
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, North America, Top Countries, 2014* 14
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 15
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 16
Proportion of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 17
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 18
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 19
Proportion of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 20
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 21
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 22
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials by Phase, 2014* 23
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 24
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 25
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 26
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Suspended Clinical Trials, 2014* 27
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Withdrawn Clinical Trials, 2014* 28
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Terminated Clinical Trials, 2014* 30
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 35
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 36
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 37
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 39
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 40
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 45
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson & Johnson, 2014* 49
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 53
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Astellas Pharma Inc., 2014* 56
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Takeda Pharmaceutical Company Limited, 2014* 58
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014* 60
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014* 62
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Medivation, Inc., 2014* 64
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 66
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Dendreon Corporation, 2014* 68
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 69
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 75
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2014* 77
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 78
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2014* 79
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Barbara Ann Karmanos Cancer Institute, 2014* 80
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Swiss Group for Clinical Cancer Research, 2014* 81
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Wisconsin Madison, 2014* 82
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014* 83

List of Figures
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials by Region (%), 2014* 9
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 10
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 11
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 12
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 13
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 14
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 15
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 16
Proportion of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 17
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 18
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 19
Proportion of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 20
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 21
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 22
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2014* 23
Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 24
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 25
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 26
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 35
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 36
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 37
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 38
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 40
GlobalData Methodology 227

To order this report: Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014
http://www.reportlinker.com/p0770879/Hormone-Refractory-Castration-Resistant-Androgen-Independent-Prostate-Cancer-Global-Clinical-Trials-Review-H1-2014.html



__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker